


AMENDMENTS TO THE SPECIFICATION

I. Please amend the paragraph at page 15, lines 11-15 as follows:

B1
"Figure 3 is a graph showing a control treatment or example with no BEC added to the bST, and two examples measuring the serum bST levels over time in calves treated with a bST composition which contained in one example ~~[Tween]~~ TWEEN® 80 (polyoxyethylene(20) sorbitan monooleate) as a BEC, and in the other example, polyoxyethylene 8 stearate (POE8S) as a BEC."

II. Please amend the paragraph at page 15, lines 24-26 as follows:

B2
"Figure 5 is a graph showing weight gain over time in mature female rodents treated with two bST compositions which contained different levels of ~~[Tween]~~ TWEEN ® 80 as the first BEC."



RECEIVED

FEB 26 2003

TECH CENTER 1600/2900

Please amend Table 1 (page 29) as follows:

Table 1.

B3

1st BEC	%1st BEC	2nd BEC	%2nd BEC	%ZnbST ¹	Hydrophobic Carrier ²
[Tween] TWEEN® 80	0.5	-	-	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	-	-	43	SO:AIMS 95:5
[Tween] TWEEN® 80	1	-	-	40.5	SO:AIMS 95:5
[Tween] TWEEN® 80	1	-	-	40.5	SO:AIMS 95:5
[Tween] TWEEN® 80	2	-	-	38	SO:AIMS 95:5
[Tween] TWEEN® 80	2	-	-	43	SO:AIMS 95:5
Hydroxypropyl beta cyclodextrin	5	-	-	38	SO:AIMS 95:5
Octylglucoside	2	-	-	38	SO:AIMS 95:5
Sucrose distearate	5	-	-	38	SO:AIMS 95:5
Sucrose stearate	5	-	-	38	SO:AIMS 95:5
Polyoxyethylene 8 stearate	2.5	-	-	38	SO:AIMS 95:5
Polyoxyethylene 8 stearate	5	-	-	39	SO:AIMS 95:6
Polyoxyethylene 50 stearate	5	-	-	38	SO:AIMS 95:5
Polyoxyethylene 100 stearate	5	-	-	38	SO:AIMS 95:5
Polyethylene glycol 20 glyceride	5	-	-	38	SO:AIMS 95:5
Pluronic® F108	2	-	-	38	SO:AIMS 95:5
Tocopherol polyethylene glycol 1000 succinate	2	-	-	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.25	NaP(mono:di=6:4)	5	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	NaP(mono:di=6:4)	2	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	NaP(mono:di=6:4)	5	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	NaP(mono:di=6:4)	8	38	SO:AIMS 95:5
[Tween] TWEEN® 80	1	NaP(mono:di=6:4)	2	38	SO:AIMS 95:5
[Tween] TWEEN® 80	1	NaP(mono:di=6:4)	5	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	Trehalose Octaacetate	5	38	SO:AIMS 95:5
[Tween] TWEEN® 80	0.5	Sucrose Octaacetate	5	38	SO:AIMS 95:5
Polyoxyethylene 8 stearate	2.5	NaP(mono:di=6:4) ³	5	36	SO:AIMS 95:5
Polyoxyethylene 8 stearate	5	NaP(mono:di=6:4)	5	36	SO:AIMS 95:5 [6]
Polyoxyethylene 8 stearate	5	NaP(monobasic)	5	36	SO:AIMS 95:5 [7]
Polyoxyethylene 8 stearate	5	Trehalose	10	34	SO:AIMS 95:5 [8]
Polyoxyethylene 8 stearate	5	Histidine-HCl	3	36	SO:AIMS 95:5 [9]

¹ZnbST = Zinc bound bovine somatotropin.

²SO:AIMS 95:5 = sesame oil (95%):aluminum monostearate (5%)

³NaP (6:4) = a 6 to 4 molar ratio mixture of the monobasic to dibasic form of the sodium phosphate salt"

IV. Please amend Table 2 (page 30) as follows:

“Table 2: bST formulati n relative potency in rodents

Description f Composition All in SO/Alms ¹	Relative Potency	Lower Limit	Higher Limit
38% ZnbST + 0.5% [Tween] TWEEN® 80	119.0	107.1	130.8
43% ZnbST + 0.5% [Tween] TWEEN® 80	125.0	113.7	136.2
40.5% ZnbST + 1% [Tween] TWEEN® 80	120.4	109.2	131.5
38% ZnbST + 2% [Tween] TWEEN® 80	114.5	99.2	129.8
43% ZnbST + 2% [Tween] TWEEN® 80	111.7	100.2	123.3
38% ZnbST + 5% Hydroxypropyl beta cyclodextrin	133.3	100.6	166.0
38% ZnbST + 5% sucrose stearate	114.3	100.3	128.4
38% ZnbST + 5% Polyoxyethylene 8 stearate	114.3	99.5	129.2
38% ZnbST + 5% Polyoxyethylene 50 stearate	121.2	105.4	137.0
38% ZnbST + 5% Polyoxyethylene 100 stearate	104.3	90.5	118.1
38% ZnbST + 5% Tocopherol polyethylene glycol 1000 succinate	104.8	93.6	116.0
38% ZnbST + 0.25% [Tween] TWEEN® 80 + 5% NaP(6:4) ²	108.5	101.1	115.8
38% ZnbST + 0.5% [Tween] TWEEN® 80 + 2% NaP(6:4)	122.4	114.2	130.7
38% ZnbST + 1% [Tween] TWEEN® 80 + 2% NaP(6:4)	114.6	107.7	121.6
38% ZnbST + 1% [Tween] TWEEN® 80 + 5% NaP(6:4)	101.3	93.6	108.9
38% ZnbST + 0.5% [Tween] TWEEN® 80 + 5% Trehalose Octaacetate	128.4	118.9	137.9

¹ SO/Alms (2.5%) = sesame oil 95%:aluminum monostearate 5%

² NaP (6:4) = a 6 to 4 molar ratio mixture of the monobasic to dibasic form of the sodium phosphate salt.”

V. Please amend the paragraph at page 32, line 8, through page 33, line 3 as follows:

“Example 5: Efficacy of Formulations Comprising POE8S or ~~[Tween]~~ TWEEN® 80 as the first Bioavailability Enhancing Constituent

The mean bST serum concentrations over 14 days in calves after receiving the polyoxyethylene 8 stearate (POE8S) or the ~~[Tween]~~ TWEEN® 80 formulation are shown in Figure 3. Compared to POSILAC®, the presence of the first BEC in the suspension formulation has improved the bST release into the circulatory system. The relative bST AUC (the BEC formulation AUC / POSILAC® AUC) is calculated to be 1.28 and 1.58 for the POE8S and

Cont
B5
[~~Tween~~] TWEEN® 80 formulation, respectively. Furthermore, the POE8S formulation demonstrates a surprising improvement in bST release duration: the circulating bST concentrations remain above the baseline at day 12 post injection. These data demonstrate a surprisingly prolonged release for the animals treated with the formulations containing POE8S.
